Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-07-07

Clinical Trial Update: Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan [Phase 2]

View source ↗

Summary

This report summarizes long-term safety data for alogliptin in Japanese participants with type 2 diabetes from a Phase 2 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nesina (alogliptin)

Snippet

Sponsor: Takeda | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED | Results posted: 2011-07-07